Privia Health Group, Inc. (PRVA) Stock Price & Analysis

Privia Health Group, Inc. (PRVA) closed at USD 22.89 on Thursday, October 22, 2026, up 1.85% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 22.47; the Oct 22, 2026 session ranged USD 22.6–23 on volume of 984,010 shares. Market capitalization is $2.92B, with a 52-week range of USD 18.92–28.82 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PRVA.md

Key facts (PRVA)

• Last four reported quarters (through Jun 30, 2026): revenue $2.36B, net income $28.1M (1.2% margin) (SEC filings).
• Valuation: P/E 103.9x (avg 142.8x at the last 3 fiscal year-ends).
• 1 of 80 tracked superinvestors hold PRVA (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 12 Form 4 filings, $15.8M; 2 not under a Rule 10b5-1 plan ($193K); 0 by opportunistic insiders, 12 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.78 on a 1–5 scale) (18 analysts), mean target USD 31.47 (range 24–40).
• Total return with dividends: 1Y -11.6% vs S&P 500 +14.9%; 5Y -3.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-05, EPS estimate USD 0.24, revenue estimate $611M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PRVA)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (PRVA)

P/E 103.9x · P/S 1.2x · P/B 3.7x · Earnings yield 0.96%

P/E at fiscal year-ends: Dec 2025 133.3x, Dec 2024 170.7x, Dec 2023 124.4x.

Superinvestors (SEC 13F-HR, Q2 2026) (PRVA)

1 of 80 tracked investors hold PRVA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (PRVA)

10 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (PRVA)

Consensus Buy (mean 1.78 on a 1–5 scale), 18 analysts; mean target USD 31.47 (low 24, high 40).

Total return (dividends reinvested) (PRVA)

PRVA revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

PRVA customer concentration

In the period ended Jun 30, 2026, 6 direct customers each accounted for at least 10% (72%, 28%, 17%, 16%, 15%, 13%) of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name them.

PRVA analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 09:23 UTC)

Technical Analysis (PRVA)

Nexqual's technical model rates PRVA "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.

Analyst Ratings (PRVA)

Wall Street analysts rate PRVA "Buy" based on 18 analysts, with a mean price target of USD 31.47 (range USD 24–40), per Nexqual as of October 23, 2026 at 09:23 UTC.

Earnings (PRVA)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financials & Fundamentals (PRVA)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Ownership (PRVA)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Leadership (PRVA)

Privia Health Group, Inc. is led by Parth Mehrotra, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.

Major Backers & Investors (PRVA)

Notable institutional backers of Privia Health Group, Inc. include FMR, LLC, Durable Capital Partners Lp, Rubicon Founders LLC , according to Nexqual as of October 23, 2026 at 09:23 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

From Privia Health Group, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• The Privia Platform is designed to succeed across demographic cohorts, acuity levels and reimbursement models, including traditional fee-for-service Medicare, the Medicare Shared Savings Program ("MSSP"), Medicare Advantage, Medicaid, commercial insurance and other existing and emerging direct contracting programs with payers and employers.
• We designed the Privia Platform to be scalable, allowing us to grow our presence in new geographic markets and guide those markets from fee-for-service ("FFS") to value-based care ("VBC"), including commercial risk, by shifting the reimbursement model and helping our Privia Providers better manage the cost of care through a focus on quality and success-based reimbursement.
• Our technology and service solutions (collectively, the "Privia Platform") are powered by our Privia Technology Solution that integrates both Privia-developed and third-party applications into a seamless interface and workflow that manages all aspects of our Privia Providers' provision of healthcare services.
• Our technology architecture utilizes API standards for ease of implementing new functionalities and integrating with multiple external systems.

Partnerships

• Nephron Research estimated in a December 2024 research report titled "Healthcare Services 2025 Outlook" that the "physician enablement" market in which we participate represents up to $2.4 trillion of that total healthcare spend.
• Our business model is designed to have meaningful revenue visibility, with low invested capital and attractive margin opportunity.

Legal & Regulatory Risks (Item 1A, quoted)

• The structure of our business model is driven by nuanced legal concepts, some of which are subject to varying interpretations. Although we and our Medical Groups strive to comply with applicable federal and state laws and regulations, governmental authorities that administer these laws or other third parties may challenge our current structure.
• Our business, financial condition and results of operations may be adversely affected by changes and uncertainty in the healthcare industry, including health reform initiatives and other changes to laws and regulations.
• We, our Medical Groups and Privia Providers, may be subject to legal proceedings, including litigation, governmental investigations and claims, and payer audits.
• The Company, its Medical Groups, and Privia Providers have been and may become subject to various legal and governmental proceedings.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt